Biosimilars and implications for pharmacy practice: Ready or not, here they come!

Biosimilars and implications for pharmacy practice: Ready or not, here they come!

Bibliographic Details
Main Authors:	Hobbs AL, Crawford JP
Format:	Article
Language:	English
Published:	Centro de Investigaciones y Publicaciones Farmaceuticas 2019-09-01
Series:	Pharmacy Practice
Subjects:	Biosimilar Pharmaceuticals Biological Therapy Therapeutic Equivalency Pharmacists Pharmacovigilance Managed Care Programs United States
Online Access:	https://pharmacypractice.org/journal/index.php/pp/article/view/1659

Similar Items

Spanish Society of Hospital Pharmacy position paper on biosimilar medicines
by: Noemí Martínez-López de Castro, et al.
Published: (2018-07-01)

Clinical and Regulatory Concerns of Biosimilars: A Review of Literature
by: Vesa Halimi, et al.
Published: (2020-08-01)

Pharmacovigilance of biosimilars – Why is it different from generics and innovator biologics?
by: B Oza, et al.
Published: (2019-01-01)

Biosimilar bidding in centralized tenders in Norway
by: Dag Morten Dalen, et al.
Published: (2021-01-01)

Tackling the challenges of nanomedicines: Are we ready?
by: Di Francesco, T., et al.
Published: (2021)

Knowledge and Perception of Iraqi Pharmacists Towards Biosimilar Medicines
by: Ashwaq J. Mohammed, et al.
Published: (2021-06-01)

Regulatory considerations for biosimilars
by: Ranjani Nellore
Published: (2010-01-01)

Navigating uncharted waters: Developing a standardized approach for evaluating and implementing biosimilar products at a comprehensive cancer center
by: Davis, J.E, et al.
Published: (2021)

The introduction of biosimilars of low molecular weight heparins in Europe: a critical review and reappraisal endorsed by the Italian Society for Haemostasis and Thrombosis (SISET) and the Italian Society for Angiology and Vascular Medicine (SIAPAV)
by: Davide Imberti, et al.
Published: (2017-05-01)

Expected Impact of Biosimilars on the Pharmaceutical Companies
by: Shiva Golshani, et al.
Published: (2021-09-01)

Knowledge and Viewpoints on Biosimilar Monoclonal Antibodies among Asian Physicians: Comparison with European Physicians
by: Soo-Kyung Park, et al.
Published: (2019-12-01)

Biosimilars: A novel perspective in diabetes therapy
by: Muthu Thiruvengadam, et al.
Published: (2020-01-01)

Knowledge, Attitude, and Practice Towards Biosimilars and Interchangeable Products: A Prescriptive Insight by the Pharmacists
by: Shakeel S, et al.
Published: (2020-11-01)

Considerations for the US health-system pharmacist in a world of biosimilars
by: Andrea Zlatkus, et al.
Published: (2020-02-01)

Medicines under additional monitoring in the European Union
by: Esther Salgueiro, et al.
Published: (2019-01-01)

A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma
by: Yuankai Shi, et al.
Published: (2020-04-01)

Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients
by: Alexandra Azevedo, et al.
Published: (2018-09-01)

Statistical considerations of noninferiority, bioequivalence and equivalence testing in biosimilars studies
by: Xu, Siyan
Published: (2016)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
by: Paweł Kawalec, et al.
Published: (2017-06-01)

Biosimilars: potential implications for clinicians
by: Eleryan MG, et al.
Published: (2016-06-01)

Real-world evidence of a successful biosimilar adoption program
by: Humphreys, S.Z
Published: (2022)

Revisión de dosieres de heparina y enoxaparina: incumplimiento de la normativa de Costa Rica para el registro sanitario de biosimilares farmacéuticos
by: Rebeca Álvarez Brenes, et al.

Clinical pharmacy practice: An activity based definition for pharmacy students of developing countries
by: Muhammad Amir
Published: (2012-01-01)

From Basic Immunology to Clinical Practice: Bio-Originators versus Bio-Similars
by: Liossis Stamatis-Nick C., et al.
Published: (2019-01-01)

An Empirical Analysis of the Perceived Challenges and Benefits of Introducing Biosimilars in Bangladesh: A Paradigm Shift
by: Eva Rahman Kabir, et al.
Published: (2018-09-01)

Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians
by: Liese Barbier, et al.
Published: (2021-06-01)

Biosimilars in rheumatology and other fields of medicine
by: Marcin Milchert, et al.
Published: (2014-07-01)

Authorisation of Non-Innovator Biotherapeutic (Biosimilar) Products in the USA
by: A. A. Soldatov, et al.
Published: (2019-03-01)

Biosimilars and Switching: What Is Your Perspective?
by: Sandoz
Published: (2017-08-01)

On the Regulatory Approval Pathway of Biosimilar Products
by: Jun Wang, et al.
Published: (2012-03-01)

Main concepts on bioequivalence and biosimilarity in the Chilean legislation, and current controversies on drug interchangeability
by: Jana Stojanova, et al.
Published: (2020-01-01)

A bibliometric analysis of the global research on biosimilars
by: Akram Hernández-Vásquez, et al.
Published: (2018-03-01)

Biosimilars: presumption of guilt
by: Marina Vladimirovna Shestakova, et al.
Published: (2011-12-01)

Safety of Use of Russian Biosimilars of Interferon Beta-1b in the Treatment of Multiple Sclerosis: a Meta-analysis of Original Studies
by: D. O. Gudz, et al.
Published: (2019-06-01)

The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC)
by: G.S. Fernandes, et al.
Published: (2018-01-01)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
by: Ioana Gherghescu, et al.
Published: (2021-12-01)

Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis
by: Bruna O. Ascef, et al.
Published: (2021-07-01)

Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review
by: Arnold G. Vulto, et al.
Published: (2020-11-01)

The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy
by: Eva Rahman Kabir, et al.
Published: (2019-08-01)

Are We Ready for Biosimilars in Gastroenterology?
by: Muhammad Ilham Abdul Hafidz, et al.
Published: (2017-12-01)

Cannot write session to /tmp/vufind_sessions/sess_paq7roq7b2bi9df31dks8ah558